Vitaxin

Vitaxin is a humanized monoclonal antibody against the vascular integrin alpha-v beta-3.[1] It is shown to be a promising angiogenesis inhibitor used in the treatment of some forms of cancer. At this time Vitaxin was in 2002 being studied for rheumatoid arthritis.[2]

References

  1. ↑ F. Vande Woude, George; George Klein (2000). Advances in Cancer Research. Academic Press. p. 27. ISBN 978-0-12-006679-7.
  2. ↑ "Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases.". PMC 1766704Freely accessible. PMID 12379637.


This article is issued from Wikipedia - version of the 11/11/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.